vimarsana.com

உலகளாவிய ஆரோக்கியம் நெருக்கடி ஒருங்கிணைப்பு மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVID turned public health experts into celebrities Not all of them are comfortable with the change

Mixing two different vaccine doses might actually strengthen COVID-19 immunity, not hurt it

Mixing two different vaccine doses might actually strengthen COVID-19 immunity, not hurt it Salon 2 hrs ago © Provided by Salon Moderna, Pfizer-BioNTech and AstraZeneca vaccine vials Three vials with different vaccines against Covid-19 by (L-R) Moderna, Pfizer-BioNTech and AstraZeneca stand on a table. THOMAS KIENZLE/AFP via Getty Images In mid-April, the New York Post ran a story about a worried patient who suffered a vaccine mix-up. Man accidentally gets one Moderna and one Pfizer COVID vaccine, the headline read.  Both the Moderna and the Pfizer coronavirus vaccines, which are being distributed in the United States, require two separate shots to be complete; the Moderna vaccine is delivered in two injections spaced 28 days apart, while for Pfizer, the difference is 21 days. 

Pfizer May Have an Anti-Viral COVID-19 Pill Available by the End of 2021

There May Be an Oral Anti-Viral COVID Pill by the End of the Year Medicine pills with the Pfizer logo are seen in this photo taken in Tehatta, West Bengal, India, on April 29, 2021. Soumyabrata Roy / NurPhoto via Getty Images By Pfizer, which along with Moderna developed successful mRNA vaccines against COVID-19 late last year, announced on Tuesday that it could have ready by the end of the year an experimental oral drug which would treat COVID-19 as soon as patients display symptoms. The announcement was made by CEO Albert Bourla on the CNBC program “Squawk Box,” who said that for the drug to be released to the public it will first need to perform well at clinical trials and receive approval by the Food and Drug Administration (FDA).

RIWI Corp : RIWI Reports Third-Highest Revenue Quarter, Focusing on Growth in 2021

RIWI Corp.: RIWI Reports Third-Highest Revenue Quarter, Focusing on Growth in 2021 Toronto, Ontario (Newsfile Corp. - April 28, 2021) - RIWI Corp. (TSXV: RIWI) (OTC Pink: RWCRF) (the Company or RIWI ), a global trend-tracking and prediction technology firm, reported its financial results for the three months ended March 31, 2021. All figures are reported in U.S. dollars unless otherwise indicated. RIWI s financial statements are prepared in accordance with International Financial Reporting Standards ( IFRS ). RIWI Highlights for the three months ended March 31, 2021 (in U.S. Dollars): RIWI posted $1,095,205 in revenue, its third-highest revenue quarter since the Company s inception. RIWI incurred a net loss of $42,639 for the three months ended March 31, 2021, due to RIWI s strategic investment in: (i) recruiting new sales personnel with expertise in RIWI s priority sales portfolios, and (ii) expanding its competitive moat through new technical feature development.

The role of religious leaders in combatting vaccine hesitancy

How religious leaders can help fight COVID vaccine hesitancy Salon 2 hrs ago Religious texts | COVID-19 Vaccine Photo illustration by Salon/Getty Images A nonpartisan and nonprofit organization that focuses on studying intersections between religion and politics released a survey on Thursday that is both hopeful and troubling: While millions of Americans remain hesitant to get a COVID-19 vaccine, religious leaders could actually help convince many people to do the safe and right thing. The Public Religion Research Institute (PRRI) found that Protestant Christians are particularly likely to be hesitant to receive vaccines, including 42% of Hispanic Protestants who are vaccine hesitant and 15% who say they do not plan on getting vaccinated; 28% of white evangelical Protestants who are vaccine hesitant and 26% who say they will not get vaccinated; and 32% of African American Protestants who say they are vaccine hesitant and 15% who say they will not

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.